Sign In
Buy BDSX
$16.10
+0.660 (+4.27%)
At Close: Jun 03, 2026
Biodesix Announces Third Quarter 2025 Results and Highlights
04:01pm, Monday, 03'rd Nov 2025
Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 millio
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
06:17am, Thursday, 30'th Oct 2025
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific Speaker panel will
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
06:17am, Wednesday, 22'nd Oct 2025
Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025
06:00am, Monday, 20'th Oct 2025
LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
06:09am, Wednesday, 15'th Oct 2025
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented One year after launch of real-world CLARIFY study, preliminary data from th
Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients
Biodesix Announces One-for-Twenty Reverse Stock Split
08:00am, Thursday, 11'th Sep 2025
LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty revers
Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference
06:00am, Friday, 05'th Sep 2025
LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
09:47am, Tuesday, 19'th Aug 2025
Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer Biodesix recently validated Thermo Fisher's tissue-based Onco
Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript
11:07am, Saturday, 09'th Aug 2025
Biodesix, Inc. (NASDAQ:BDSX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Robin Harper Cowie - CFO, Secretary & Treasurer Scott Hutton - President, CEO & Director C
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
06:21pm, Thursday, 07'th Aug 2025
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.08 per share a year ago.
Biodesix Announces Second Quarter 2025 Results and Highlights
04:06pm, Thursday, 07'th Aug 2025
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 m
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
06:00am, Tuesday, 05'th Aug 2025
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief F
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
06:00am, Thursday, 24'th Jul 2025
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarte
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs Nation's first CME-accredited course for APPs on clinical
